Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma

H. Shimizu, T. Saitoh, M. Tanaka, Takehiko Mori, T. Sakura, N. Kawai, Y. Kanda, C. Nakaseko, S. Yano, H. Fujita, S. Fujisawa, S. Miyawaki, H. Kanamori, Shinichiro Okamoto

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We recently reported that adult acute myeloid leukemia (AML) patients with granulocytic sarcoma (GS) possessed unique clinical features and poor prognosis. However, the optimal therapeutic strategy for this entity has not been established. Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the management of AML with GS. We retrospectively analyzed 503 consecutive adult AML patients (median age, 44 years; range, 15-73 years) who received allo-HSCT. A total of 44 patients (8.7%) had GS before transplantation. Patients with GS achieved comparable survival to those without GS (5-year overall survival (OS), 47% vs 44%, respectively, P=0.621). In patients with GS, excellent outcomes were seen in those that underwent allo-HSCT while in complete remission, whereas nine out of ten patients with GS at the time of transplant experienced a relapse within 6 months after allo-HSCT. Local irradiation for GS prior to allo-HSCT and acute and chronic graft-versus-host disease did not affect survival significantly. Multivariate analysis identified age, disease status and the use of myeloablative conditioning as independent prognostic factors for OS. These data suggest that better control of GS prior to allo-HSCT is crucial to improve the outcome of transplantation for those with GS.

Original languageEnglish
Pages (from-to)2469-2473
Number of pages5
JournalLeukemia
Volume26
Issue number12
DOIs
Publication statusPublished - 2012 Dec

Fingerprint

Myeloid Sarcoma
Hematopoietic Stem Cell Transplantation
Acute Myeloid Leukemia
Survival
Transplantation
Graft vs Host Disease
Multivariate Analysis

Keywords

  • acute myeloid leukemia
  • allogeneic stem cell transplantation
  • granulocytic sarcoma

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. / Shimizu, H.; Saitoh, T.; Tanaka, M.; Mori, Takehiko; Sakura, T.; Kawai, N.; Kanda, Y.; Nakaseko, C.; Yano, S.; Fujita, H.; Fujisawa, S.; Miyawaki, S.; Kanamori, H.; Okamoto, Shinichiro.

In: Leukemia, Vol. 26, No. 12, 12.2012, p. 2469-2473.

Research output: Contribution to journalArticle

Shimizu, H, Saitoh, T, Tanaka, M, Mori, T, Sakura, T, Kawai, N, Kanda, Y, Nakaseko, C, Yano, S, Fujita, H, Fujisawa, S, Miyawaki, S, Kanamori, H & Okamoto, S 2012, 'Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma', Leukemia, vol. 26, no. 12, pp. 2469-2473. https://doi.org/10.1038/leu.2012.156
Shimizu, H. ; Saitoh, T. ; Tanaka, M. ; Mori, Takehiko ; Sakura, T. ; Kawai, N. ; Kanda, Y. ; Nakaseko, C. ; Yano, S. ; Fujita, H. ; Fujisawa, S. ; Miyawaki, S. ; Kanamori, H. ; Okamoto, Shinichiro. / Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. In: Leukemia. 2012 ; Vol. 26, No. 12. pp. 2469-2473.
@article{ab5c665b2d744a57ac33a66569c82f95,
title = "Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma",
abstract = "We recently reported that adult acute myeloid leukemia (AML) patients with granulocytic sarcoma (GS) possessed unique clinical features and poor prognosis. However, the optimal therapeutic strategy for this entity has not been established. Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the management of AML with GS. We retrospectively analyzed 503 consecutive adult AML patients (median age, 44 years; range, 15-73 years) who received allo-HSCT. A total of 44 patients (8.7{\%}) had GS before transplantation. Patients with GS achieved comparable survival to those without GS (5-year overall survival (OS), 47{\%} vs 44{\%}, respectively, P=0.621). In patients with GS, excellent outcomes were seen in those that underwent allo-HSCT while in complete remission, whereas nine out of ten patients with GS at the time of transplant experienced a relapse within 6 months after allo-HSCT. Local irradiation for GS prior to allo-HSCT and acute and chronic graft-versus-host disease did not affect survival significantly. Multivariate analysis identified age, disease status and the use of myeloablative conditioning as independent prognostic factors for OS. These data suggest that better control of GS prior to allo-HSCT is crucial to improve the outcome of transplantation for those with GS.",
keywords = "acute myeloid leukemia, allogeneic stem cell transplantation, granulocytic sarcoma",
author = "H. Shimizu and T. Saitoh and M. Tanaka and Takehiko Mori and T. Sakura and N. Kawai and Y. Kanda and C. Nakaseko and S. Yano and H. Fujita and S. Fujisawa and S. Miyawaki and H. Kanamori and Shinichiro Okamoto",
year = "2012",
month = "12",
doi = "10.1038/leu.2012.156",
language = "English",
volume = "26",
pages = "2469--2473",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma

AU - Shimizu, H.

AU - Saitoh, T.

AU - Tanaka, M.

AU - Mori, Takehiko

AU - Sakura, T.

AU - Kawai, N.

AU - Kanda, Y.

AU - Nakaseko, C.

AU - Yano, S.

AU - Fujita, H.

AU - Fujisawa, S.

AU - Miyawaki, S.

AU - Kanamori, H.

AU - Okamoto, Shinichiro

PY - 2012/12

Y1 - 2012/12

N2 - We recently reported that adult acute myeloid leukemia (AML) patients with granulocytic sarcoma (GS) possessed unique clinical features and poor prognosis. However, the optimal therapeutic strategy for this entity has not been established. Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the management of AML with GS. We retrospectively analyzed 503 consecutive adult AML patients (median age, 44 years; range, 15-73 years) who received allo-HSCT. A total of 44 patients (8.7%) had GS before transplantation. Patients with GS achieved comparable survival to those without GS (5-year overall survival (OS), 47% vs 44%, respectively, P=0.621). In patients with GS, excellent outcomes were seen in those that underwent allo-HSCT while in complete remission, whereas nine out of ten patients with GS at the time of transplant experienced a relapse within 6 months after allo-HSCT. Local irradiation for GS prior to allo-HSCT and acute and chronic graft-versus-host disease did not affect survival significantly. Multivariate analysis identified age, disease status and the use of myeloablative conditioning as independent prognostic factors for OS. These data suggest that better control of GS prior to allo-HSCT is crucial to improve the outcome of transplantation for those with GS.

AB - We recently reported that adult acute myeloid leukemia (AML) patients with granulocytic sarcoma (GS) possessed unique clinical features and poor prognosis. However, the optimal therapeutic strategy for this entity has not been established. Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the management of AML with GS. We retrospectively analyzed 503 consecutive adult AML patients (median age, 44 years; range, 15-73 years) who received allo-HSCT. A total of 44 patients (8.7%) had GS before transplantation. Patients with GS achieved comparable survival to those without GS (5-year overall survival (OS), 47% vs 44%, respectively, P=0.621). In patients with GS, excellent outcomes were seen in those that underwent allo-HSCT while in complete remission, whereas nine out of ten patients with GS at the time of transplant experienced a relapse within 6 months after allo-HSCT. Local irradiation for GS prior to allo-HSCT and acute and chronic graft-versus-host disease did not affect survival significantly. Multivariate analysis identified age, disease status and the use of myeloablative conditioning as independent prognostic factors for OS. These data suggest that better control of GS prior to allo-HSCT is crucial to improve the outcome of transplantation for those with GS.

KW - acute myeloid leukemia

KW - allogeneic stem cell transplantation

KW - granulocytic sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84871180413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871180413&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.156

DO - 10.1038/leu.2012.156

M3 - Article

VL - 26

SP - 2469

EP - 2473

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -